S&P DJI Announces March 2025 Quarterly Rebalance
Filed with ASX · · 8 pages · English
EMvision Medical Devices Ltd. on 6ix
Earlier from EMvision Medical Devices
- EMVision Releases its FY25 Half Yearly Report
- US Ethics Approval Received for Pivotal Validation Trial
- EMVision Receives $2.12m R&D Tax Rebate
- Algorithms Deliver Excellent Results In EMView Study
- EMV Prepares for Trial Following Positive FDA Engagement
Later from EMvision Medical Devices
- First Responder Scanner in Successful Aeromedical Testing
- Emu Pivotal Validation Trial Commences
- Activation of Second US Pivotal Trial Site, Mayo Clinic
- Enhanced Algorithm Performance From Continuous Innovation
- Additional Pivotal Trial Site Activations
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices